AbbVie (NASDAQ:ABBV) is basically a one-trick pony. The trick is an immunosuppressant called Humira, prescribed to fight rheumatoid arthritis and other conditions. It’s the best-selling drug in the world, bringing in $18.4 billion in 2017, but that might not be sufficient to support the future of AbbVie stock. While protected against direct competition in the U.S. until 2023, Humira is already facing biosimilars in Europe, as its protections there disappear.
For now, the good times roll on. AbbVie is due to report earnings Jan. 25, expecting sales of $8.36 billion for a 2018 total of $32.8 billion , 16% ahead of 2017’s $28.2 billion. Net income of $1.92 per share will bring that total to $6.92 per share for the year. But, as they say of both athletes and great beauties, Father Time is undefeated. AbbVie still faces a patent cliff, and growing opposition to rising prices. Nothing lasts forever. What works this year may not work next year. Know that before you buy AbbVie stock.
Source: InvestorPlace
Related Articles:
- 2 Low P/E Value-Stocks, Yielding 4% Or Higher
- 5 Stocks With A Low Debt To Total Capital
- Should You Sell A Dividend Stock After A Dividend Cut?
- All Investing Involves Risk
- 4 Dividend Stocks With Room To Increase Their Payout
________________________________________________________________
Subscribe to:
Post Comments (Atom)
Popular Posts Last 30 Days
-
Utility stocks have been relatively volatile in the recent past. However, most utility stocks have a low beta and have a stable cash flow vi...
-
Many investors search for safe, dividend-paying stocks. As John D. Rockefeller once said: "Do you know the only thing that gives me ple...
-
With interest rates near zero, many investors are turning to dividend stocks for income. And for some investors, the higher the yield, the b...
-
Dividend stocks have fallen out of fashion during the pandemic. With interest rates at rock-bottom levels, investors have fled from assets l...
-
One way to identify suitable candidates is to look for stocks with an average dividend yield of 3%, and positive average annual dividend gro...
-
The rollout of fifth-generation network services, also known as 5G, enhances the appeal of each of these three dividend-paying, 5G technolog...
-
Energy Transfer (NYSE:ET) pays a monster cash distribution. Given the big slide in its unit price, -- they're down more than 50% in the ...
-
With interest rates stuck below 1%, finding income in today's market can be difficult. Therefore it makes sense for income investors to ...
-
These stocks have superior fundamentals that make dividend growth a quality and promising investment for the long term. These include a sust...
-
Unfortunately, some investors that are new to dividend stocks end up chasing the highest yield stocks they can find and end up getting burne...
0 comments
Post a Comment
Post a Comment
Note: Only a member of this blog may post a comment.